Q-omics provides the consensus-scored SKOR2 profile across patient tissues and cancer cell-line models. SKOR2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SKOR2 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SKOR2 RNA expression shows 8,128 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, COAD, and TGCT as cancer lineages where SKOR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SKOR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SKOR2 survival associations across molecular data types. SKOR2 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SKOR2 RNA expression–survival associations across cancer types. High SKOR2 expression shows unfavorable associations in UCS, KICH, BLCA, ACC and KIRC, but favorable associations in CESC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SKOR2 RNA expression.
This table summarizes SKOR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SKOR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SKOR2 shows higher tumor expression in COAD, LUAD, KICH and THCA. The COAD box plot shows higher SKOR2 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .003).
This table shows molecular features associated with SKOR2 in patient tissues and cancer cell lines. In patient samples, SKOR2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SKOR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
